Market Overview

UPDATE: Goldman Sachs Downgrades Cepheid to Neutral on Lack of Catalysts

Related CPHD
Morning Market Losers
Benzinga's Top Downgrades
Launch Delays The Wrong Prescription For GenMark Shares (Seeking Alpha)

Goldman Sachs reduced its rating on Cepheid (NASDAQ: CPHD) from Buy to Neutral and reduced its price target from $42 to $32.

Goldman Sachs commented, "We downgrade shares of CPHD to Neutral from Buy and lower our 6-month price target to $32 ($42 previously) as we believe CPHD is now a “show-me” story that requires several quarters of solid management execution (following several missteps) to garner the premium valuation is had previously ascertained. Since adding CPHD to the Buy List on 9/23/11, the shares are -19.3% vs. the S&P 500 +19.7%, given operational missteps and slowing growth. Over the past 12 months, CPHD is -8.2% vs. S&P 500 +9.9%."

Cepheid closed at $30.53 on Friday.

Latest Ratings for CPHD

Jul 2015Evercore PartnersDowngradesHoldSell
Jun 2015Craig-HallumUpgradesHoldBuy
Apr 2015JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (CPHD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters